Phase II study of NS-17 in elderly patients with acute myeloid leukemia.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223699

Enrollment

Registered

2017-11-01

Start date

2018-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

investigational material(s) Generic name etc : NS-17 INN of investigational material : Azacitidine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. AML patients who are diagnosed of one of the following: Newly diagnosed, histologically confirmed de novo AML or, AML secondary to prior myelodysplastic disease or, AML secondary to exposure to potentially leukemogenic therapies or agents with the primary malignancy. 2. Patients with bone marrow blasts>=30%. 3. Patients whose ECOG PS is 0, 1 or 2

Exclusion criteria

Exclusion criteria: 1. Patients with previous cytotoxic treatment for AML. 2. Patients with previous treatment with hypomethylating agents or cytarabine.

Design outcomes

Primary

Measure	Time frame
efficacy Overall survival	—

Secondary

Measure	Time frame
efficacy One-year overall survival rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026